Both Cdkn2a and Cdkn2b are expressed at very high levels in day 1 BC and SM cells under normal conditions (Fig. 3); a lower expression of these genes upon AP-1 inhibition would preferentially enhance the proliferation of SM cells compared with HE or HP cells. Here, CDKN2B is linked to breast cancer.